Search Results - "Davis, Ian D"

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd? by Davis, Ian D.

“…The mainstay of treatment for metastatic prostate cancer is androgen deprivation therapy (ADT). Outcomes with ADT are variable but control of hormone-sensitive…”
Get full text

TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) by Hofman, Michael S., Emmett, Louise, Violet, John, Y. Zhang, Alison, Lawrence, Nicola J., Stockler, Martin, Francis, Roslyn J., Iravani, Amir, Williams, Scott, Azad, Arun, Martin, Andrew, McJannett, Margaret, Davis, Ian D.

“…Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that…”
Get full text

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial by Sternberg, Cora N, Davis, Ian D, Mardiak, Jozef, Szczylik, Cezary, Lee, Eunsik, Wagstaff, John, Barrios, Carlos H, Salman, Pamela, Gladkov, Oleg A, Kavina, Alexander, Zarbá, Juan J, Chen, Mei, McCann, Lauren, Pandite, Lini, Roychowdhury, Debasish F, Hawkins, Robert E

“…PURPOSE Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit…”
Get full text

Breast and prostate cancer: more similar than different by Risbridger, Gail P, Davis, Ian D, Birrell, Stephen N, Tilley, Wayne D

“…This Opinion article discusses some key similarities between breast and prostate cancer, with a focus on hormone and hormone receptor involvement…”
Get full text

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial by Motzer, Robert J, Dr Prof, Porta, Camillo, MD, Vogelzang, Nicholas J, Prof, Sternberg, Cora N, MD, Szczylik, Cezary, Prof, Zolnierek, Jakub, MD, Kollmannsberger, Christian, MD, Rha, Sun Young, MD, Bjarnason, Georg A, MD, Melichar, Bohuslav, Prof, De Giorgi, Ugo, MD, Grünwald, Viktor, Prof, Davis, Ian D, MBBS, Lee, Jae-Lyun, Prof, Esteban, Emilio, Prof, Urbanowitz, Gladys, MBA, Cai, Can, PhD, Squires, Matthew, PhD, Marker, Mahtab, PhD, Shi, Michael M, MD, Escudier, Bernard, Prof

“…Summary Background An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor…”
Get full text

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial by Chambers, Suzanne K, Occhipinti, Stefano, Foley, Elizabeth, Clutton, Samantha, Legg, Melissa, Berry, Martin, Stockler, Martin R, Frydenberg, Mark, Gardiner, Robert A, Lepore, Stephen J, Davis, Ian D, Smith, David P

“…Purpose Advanced prostate cancer (PC) is associated with substantial psychosocial morbidity. We sought to determine whether mindfulness-based cognitive therapy…”
Get full text

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma by HUTSON, Thomas E, DAVIS, Ian D, PANDITE, Lini, FIGLIN, Robert A, MACHIELS, Jean-Pascal H, DE SOUZA, Paul L, ROTTEY, Sylvie, HONG, Bao-Fa, EPSTEIN, Richard J, BAKER, Katherine L, MCCANN, Lauren, CROFTS, Theresa

“…Inactivation of the von Hippel-Lindau gene in clear-cell renal cell carcinomas (RCC) leads to overexpression of hypoxia inducible factor, a transcription…”
Get full text

Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas by QI ZHAO, CABALLERO, Otavia L, DAVIS, Ian D, JONASCH, Eric, TAMBOLI, Pheroze, YUNG, W. K. Alfred, WEINSTEIN, John N, SHAW, Kenna, STRAUSBERG, Robert L, JUN YAO

“…We aim to identify tumor-specific alternative splicing events having potential applications in the early detection, diagnosis, prognosis, and therapy for…”
Get full text

The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer by Whitford, Hayley S., Kalinowski, Pawel, Schembri, Adrian, Grimison, Peter, Stockler, Martin, Martin, Andrew, Toner, Guy C., Davis, Ian D., Maruff, Paul, Olver, Ian N.

“…Purpose The causal link between chemotherapy and cognitive impairment is unclear. We studied testicular cancer patients’ objective and subjective cognitive…”
Get full text

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer by Mak, Blossom, Lin, Hui-Ming, Kwan, Edmond M, Fettke, Heidi, Tran, Ben, Davis, Ian D, Mahon, Kate, Stockler, Martin R, Briscoe, Karen, Marx, Gavin, Zhang, Alison, Crumbaker, Megan, Tan, Winston, Huynh, Kevin, Meikle, Thomas G, Mellett, Natalie A, Hoy, Andrew J, Du, Pan, Yu, Jianjun, Jia, Shidong, Joshua, Anthony M, Waugh, David J, Butler, Lisa M, Kohli, Manish, Meikle, Peter J, Azad, Arun A, Horvath, Lisa G

“…Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually…”
Get full text

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma by Grossmann, Mathis, Premaratne, Erosha, Desai, Jayesh, Davis, Ian D.

“…Summary Context  Sunitinib malate is an oral tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal…”
Get full text

Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011 by Evans, Sue M, Millar, Jeremy L, Davis, Ian D, Murphy, Declan G, Bolton, Damien M, Giles, Graham G, Frydenberg, Mark, Andrianopoulos, Nick, Wood, Julie M, Frauman, Albert G, Costello, Anthony J, McNeil, John J

“…Objective: To describe patterns of care for men diagnosed with prostate cancer in Victoria, Australia, between 2008 and 2011. Design, setting and patients: Men…”
Get full text

Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial by Davis, Ian D, Brady, Ben, Kefford, Richard F, Millward, Michael, Cebon, Jonathan, Skrumsager, Birte K, Mouritzen, Ulrik, Hansen, Lasse Tengbjerg, Skak, Kresten, Lundsgaard, Dorthe, Frederiksen, Klaus Stensgaard, Kristjansen, Paul E G, McArthur, Grant

“…Purpose: Human interleukin-21 (IL-21) is a class I cytokine that mediates activation of CD8 + T cells, natural killer (NK) cells, and other cell types. We…”
Get full text

A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma by Ebert, Lisa M, MacRaild, Sarah E, Zanker, Damien, Davis, Ian D, Cebon, Jonathan, Chen, Weisan

“…Cancer vaccines are designed to expand tumor antigen-specific T cells with effector function. However, they may also inadvertently expand regulatory T cells…”
Get full text

Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage by Barrow, Catherine, Browning, Judy, MacGregor, Duncan, Davis, Ian D, Sturrock, Sue, Jungbluth, Achim A, Cebon, Jonathan

“…Purpose: Melanoma cells express antigens that can induce T-cell and antibody responses. Obtaining a detailed understanding of antigen expression in primary and…”
Get full text

Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma by NICHOLAOU, Theo, EBERT, Lisa M, LINDA PAN, VENHAUS, Ralph, HOFFMAN, Eric W, CHEN, Weisan, CEBON, Jonathan, DAVIS, Ian D, MCARTHUR, Grant A, JACKSON, Heather, DIMOPOULOS, Nektaria, TAN, Bee, MARASKOVSKY, Eugene, MILORADOVIC, Lena, HOPKINS, Wendie

“…Purpose: NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently…”
Get full text

Be Careful Not To ARAMIS the Point by Davis, Ian D.

Get full text

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial by Guo, Jun, Jin, Jie, Oya, Mototsugu, Uemura, Hirotsugu, Takahashi, Shunji, Tatsugami, Katsunori, Rha, Sun Young, Lee, Jae-Lyun, Chung, Jinsoo, Lim, Ho Yeong, Wu, Hsi Chin, Chang, Yen Hwa, Azad, Arun, Davis, Ian D, Carrasco-Alfonso, Marlene J, Nanua, Bhupinder, Han, Jackie, Ahmad, Qasim, Motzer, Robert

“…The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced…”
Get full text

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase by Lin, Hui-Ming, Mak, Blossom, Yeung, Nicole, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate L., Zhang, Alison, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Crumbaker, Megan, Stricker, Phillip D., Du, Pan, Yu, Jianjun, Jia, Shidong, Scheinberg, Tahlia, Fitzpatrick, Michael, Bonnitcha, Paul, Sullivan, David R., Joshua, Anthony M., Azad, Arun A., Butler, Lisa M., Meikle, Peter J., Horvath, Lisa G.

“…Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20–30% of men with metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma by Davis, Ian D, Skrumsager, Birte K, Cebon, Jonathan, Nicholaou, Theo, Barlow, John W, Moller, Niels Peter Hundahl, Skak, Kresten, Lundsgaard, Dorthe, Frederiksen, Klaus Stensgaard, Thygesen, Peter, McArthur, Grant A

“…Purpose: Human interleukin-21 (IL-21) is a pleiotropic class I cytokine that activates CD8 + T cells and natural killer cells. We report a phase 1 study of…”
Get full text